{
  "emaEpar": [
    {
      "activeSubstance": "nelarabine",
      "conditionIndication": "Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.Due to the small patient populations in these disease settings, the information to support theseindications is based on limited data.",
      "inn": "nelarabine",
      "marketingAuthorisationDate": "2007-08-22 00:00:00",
      "marketingAuthorisationHolder": "Novartis Europharm Limited",
      "medicineName": "Atriance",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/atriance"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "Arranon",
      "indication": "1 INDICATIONS AND USAGE ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )",
      "manufacturer": "Novartis Pharmaceuticals Corporation",
      "splSetId": "fffa5d75-0dba-4ad7-a252-5f60fa28489a"
    }
  ],
  "id": "Nelarabine",
  "nciThesaurus": {
    "casRegistry": "121032-29-9",
    "chebiId": "CHEBI:63612",
    "chemicalFormula": "C11H15N5O5",
    "definition": "An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells.",
    "fdaUniiCode": "60158CV180",
    "identifier": "C1704",
    "preferredName": "Nelarabine",
    "semanticType": "Nucleic Acid, Nucleoside, or Nucleotide",
    "subclassOf": [
      "C1556"
    ],
    "synonyms": [
      "2-Amino, 6-Methoxypurine Arabinoside",
      "2-Amino-6-methoxypurine arabinoside",
      "2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine",
      "506U78",
      "Arranon",
      "Compound 506U78",
      "GW506U78",
      "NELARABINE",
      "Nelarabine",
      "nelarabine"
    ]
  }
}